Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.

Calcitonin gene–related peptide Migraine Safety Tolerability

Journal

The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562

Informations de publication

Date de publication:
11 Mar 2024
Historique:
received: 08 12 2023
accepted: 23 02 2024
medline: 11 3 2024
pubmed: 11 3 2024
entrez: 11 3 2024
Statut: epublish

Résumé

Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine symptoms, improve function, and enhance quality of life. Atogepant is a migraine-specific oral calcitonin gene-related peptide receptor antagonist that is indicated for the preventive treatment of migraine in adults. This analysis evaluated the safety and tolerability profile of atogepant for the preventive treatment of migraine, including adverse events (AEs) of interest, such as constipation, nausea, hepatic safety, weight changes, and cardiac disorders. This post hoc analysis was performed using data pooled from 2 (12-week) randomized, double-blind, placebo-controlled trials (RCTs) and 2 (40- and 52-week) open-label long-term safety (LTS) trials of oral atogepant for episodic migraine (EM). The safety population included 1550 participants from the pooled RCTs (atogepant, n = 1142; placebo, n = 408) and 1424 participants from the pooled LTS trials (atogepant, n = 1228; standard care [SC], n = 196). In total, 643/1142 (56.3%) atogepant participants and 218/408 (53.4%) placebo participants experienced ≥ 1 treatment-emergent AEs (TEAEs) in the RCTs. In the LTS trials, 792/1228 (64.5%) of atogepant participants and 154/196 (78.6%) of SC participants experienced ≥ 1 TEAEs. The most commonly reported TEAEs (≥ 5%) in participants who received atogepant once daily were upper respiratory tract infection (5.3% in RCTs, 7.7% in LTS trials), constipation (6.1% in RCTs, 5.0% in LTS trials), nausea (6.6% in RCTs, 4.6% in LTS trials), and urinary tract infection (3.4% in RCTs, 5.2% in LTS trials). Additionally, weight loss appeared to be dose- and duration-dependent. Most TEAEs were considered unrelated to study drug and few led to discontinuation. Overall, atogepant is safe and well tolerated in pooled RCTs and LTS trials for the preventive treatment of EM in adults. ClinicalTrials.gov identifiers: NCT02848326 (MD-01), NCT03777059 (ADVANCE), NCT03700320 (study 302), NCT03939312 (study 309).

Sections du résumé

BACKGROUND BACKGROUND
Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine symptoms, improve function, and enhance quality of life. Atogepant is a migraine-specific oral calcitonin gene-related peptide receptor antagonist that is indicated for the preventive treatment of migraine in adults. This analysis evaluated the safety and tolerability profile of atogepant for the preventive treatment of migraine, including adverse events (AEs) of interest, such as constipation, nausea, hepatic safety, weight changes, and cardiac disorders.
METHODS METHODS
This post hoc analysis was performed using data pooled from 2 (12-week) randomized, double-blind, placebo-controlled trials (RCTs) and 2 (40- and 52-week) open-label long-term safety (LTS) trials of oral atogepant for episodic migraine (EM).
RESULTS RESULTS
The safety population included 1550 participants from the pooled RCTs (atogepant, n = 1142; placebo, n = 408) and 1424 participants from the pooled LTS trials (atogepant, n = 1228; standard care [SC], n = 196). In total, 643/1142 (56.3%) atogepant participants and 218/408 (53.4%) placebo participants experienced ≥ 1 treatment-emergent AEs (TEAEs) in the RCTs. In the LTS trials, 792/1228 (64.5%) of atogepant participants and 154/196 (78.6%) of SC participants experienced ≥ 1 TEAEs. The most commonly reported TEAEs (≥ 5%) in participants who received atogepant once daily were upper respiratory tract infection (5.3% in RCTs, 7.7% in LTS trials), constipation (6.1% in RCTs, 5.0% in LTS trials), nausea (6.6% in RCTs, 4.6% in LTS trials), and urinary tract infection (3.4% in RCTs, 5.2% in LTS trials). Additionally, weight loss appeared to be dose- and duration-dependent. Most TEAEs were considered unrelated to study drug and few led to discontinuation.
CONCLUSIONS CONCLUSIONS
Overall, atogepant is safe and well tolerated in pooled RCTs and LTS trials for the preventive treatment of EM in adults.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov identifiers: NCT02848326 (MD-01), NCT03777059 (ADVANCE), NCT03700320 (study 302), NCT03939312 (study 309).

Identifiants

pubmed: 38462625
doi: 10.1186/s10194-024-01736-z
pii: 10.1186/s10194-024-01736-z
doi:

Banques de données

ClinicalTrials.gov
['NCT03939312', 'NCT03700320', 'NCT03777059', 'NCT02848326']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Informations de copyright

© 2024. The Author(s).

Références

Ashina M (2020) Migraine. N Engl J Med 383:1866–1876
doi: 10.1056/NEJMra1915327 pubmed: 33211930
Ailani J, Burch RC, Robbins MS (2021) The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021–1039
doi: 10.1111/head.14153 pubmed: 34160823
American Headache Society (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59:1–18
doi: 10.1111/head.13456
Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17:501–514
doi: 10.1038/s41582-021-00509-5 pubmed: 34145431 pmcid: 8321897
Qulipta (2023) AbbVie
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K et al (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol 19:727–737
doi: 10.1016/S1474-4422(20)30234-9 pubmed: 32822633
Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695–706
doi: 10.1056/NEJMoa2035908 pubmed: 34407343
Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J et al (2023) Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase 3 trial. Headache 63:79–88
doi: 10.1111/head.14439 pubmed: 36651532 pmcid: 10107835
Messina R, Goadsby PJ (2019) CGRP—a target for acute therapy in migraine: clinical data. Cephalalgia 39:420–427
doi: 10.1177/0333102418768095 pubmed: 29616830
Negro A, Lionetto L, Simmaco M, Martelletti P (2012) CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 21:807–818
doi: 10.1517/13543784.2012.681044 pubmed: 22512641
de Vries LS, van der Arend BWH, Maassen VanDenBrink A, Terwindt GM (2022) Blood pressure in patients with migraine treated with monoclonal anti-CGRP (receptor) antibodies: a prospective follow-up study. Neurology 99:e1897–e1904
Robblee J, Harvey LK (2022) Cardiovascular disease and migraine: are the new treatments safe? Curr Pain Headache Rep 26:647–655
doi: 10.1007/s11916-022-01064-4 pubmed: 35751798
Kristoffersen ES, Børte S, Hagen K, Zwart JA, Winsvold BS (2020) Migraine, obesity and body fat distribution—a population-based study. J Headache Pain 21:97
doi: 10.1186/s10194-020-01163-w pubmed: 32762643 pmcid: 7409451
Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J et al (2023) Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia 43:3331024221128250
doi: 10.1177/03331024221128250 pubmed: 36620892
Headache Classification Committee of the International Headache Society (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211
doi: 10.1177/0333102417738202
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U et al (2023) Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402:775–785
doi: 10.1016/S0140-6736(23)01049-8 pubmed: 37516125
Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H et al (2022) Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia 42:3–11
doi: 10.1177/03331024211042385 pubmed: 34521260
Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V et al (2021) Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain 22:16
doi: 10.1186/s10194-021-01227-5 pubmed: 33781209 pmcid: 8008612
Lampl C, Kraus V, Lehner K, Loop B, Chehrenama M, Maczynska Z et al (2022) Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials. J Headache Pain 23:104
doi: 10.1186/s10194-022-01470-4 pubmed: 35978286 pmcid: 9386939
Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338–350
doi: 10.1038/s41582-018-0003-1 pubmed: 29691490
Blumenfeld AM, Pavlovic JM, Harriott A, Best PJ, Monteith T, Ferreira R et al (2022) Post-hoc analysis evaluating safety of atogepant in ADVANCE & open-label extension participants with cardiovascular risk factors [abstract P-137]. Headache 62(suppl 1):119
Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ et al (2019) Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39:1798–1808
doi: 10.1177/0333102419888222 pubmed: 31707815

Auteurs

Paul Rizzoli (P)

Brigham and Women's Hospital, Boston, MA, USA.

Michael J Marmura (MJ)

Department of Neurology, Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA.

Jennifer Robblee (J)

Barrow Neurological Institute, Phoenix, AZ, USA.

Jennifer McVige (J)

DENT Neurologic Institute, Amherst, NY, USA.

Sara Sacco (S)

Carolinas Headache Clinic, Matthews, NC, USA.

Stephanie J Nahas (SJ)

Department of Neurology, Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA.

Jessica Ailani (J)

MedStar Georgetown University Hospital, Washington, DC, USA.

Rosa De Abreu Ferreira (R)

AbbVie, 1 N. Waukegan Rd, North Chicago, IL, 60064, USA.

Julia Ma (J)

AbbVie, Florham Park, NJ, USA.

Jonathan H Smith (JH)

AbbVie, 1 N. Waukegan Rd, North Chicago, IL, 60064, USA.

Brett Dabruzzo (B)

AbbVie, 1 N. Waukegan Rd, North Chicago, IL, 60064, USA. brett.dabruzzo@abbvie.com.

Messoud Ashina (M)

Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Classifications MeSH